Skip to main content
SpringerLink
Log in
Book cover

Gestational Trophoblastic Disease pp 71–78Cite as

Management of Low-Risk Gestational Trophoblastic Neoplasia

  • Chapter
  • First Online:

Abstract

Gestational Trophoblastic Disease (GTD) is a rare disease. Worldwide, the incidences vary by regions with low rates found in some parts of South America, Europe, and North America [1] whilst countries in East-Asia report higher rates. Advances in prenatal imaging, immune-histological staining, and DNA ploidy technology help improve making a diagnosis [2–5].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4:670–8.

    Article  Google Scholar 

  2. Osterheld MC, Caron L, Meagher CP, Villemure K. Combination of immunohistochemistry and ploidy analysis to assist histopathological diagnosis of molar. Clin Med Pathol. 2008;1:61–7. https://doi.org/10.4137/cpath.s601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ronnett BM. Hydatidiform moles. Ancillary techniques to refine diagnosis. Arch Pathol Lab Med. 2018;142:1485–502. https://doi.org/10.5858/arpa.2018-0226-RA.

    Article  PubMed  Google Scholar 

  4. Hemming JD, Quirke P, Womack C, Wells M, Elston CW. Diagnosis of molar pregnancy and persistent trophoblastic disease by flow cytometry. J Clin Pathol. 1987;40:615–20.

    Article  CAS  Google Scholar 

  5. Khashaba M, Arafa M, Elsalkh E, Hemida R, Kandil W. Morphological features and immunohistochemical expression of p57Kip2 in early molar pregnancies and their relations to the progression to persistent trophoblastic disease. J Pathol Transl Med. 2017;51(4):381–7. https://doi.org/10.4132/jptm.2017.04.28.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gockley AA, Melamed A, Joseph NT, Clapp M, Berkowitz RS. Effect of race/ethnicity on risk of complete and partial molar pregnancy. Gynecol Oncol. 2016;140(3):470–3. https://doi.org/10.1016/j.ygyno.2016.01.005.

    Article  PubMed  Google Scholar 

  7. Bracken MB. Incidence and aetiology of hydatidiform mole: an epidemiological review. BJOG Int J Obstet Gynaecol. 1987;94:1123–35. https://doi.org/10.1111/j.1471-0528.1987.tb02311.x.

    Article  CAS  Google Scholar 

  8. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9. https://doi.org/10.1016/j.ajog.2010.06.073.

    Article  PubMed  Google Scholar 

  9. Maestá I, Berkowitz RS, Goldstein DP, Bernstein MR, Ramírez LA, Horowitz NS. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2015;138(1):50–4.

    Article  Google Scholar 

  10. Feltmate CM, Grwdon WB, Wolfberg AJ, Goldstein DP, Genest DR, Chinchila ME, Berkowitz RS. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51(11):902–6.

    PubMed  Google Scholar 

  11. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet. 2018;143:79–85. https://doi.org/10.1002/ijgo.12615.

    Article  Google Scholar 

  12. Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, Seckl MJ. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? Eur J Obstet Gynecol Reprod Biol. 2018;223:50–5. https://doi.org/10.1016/j.ejogrb.2018.02.001.

    Article  CAS  PubMed  Google Scholar 

  13. Wiesma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M. Persistent trophoblast disease following partial molar pregnancy. Aust New Zealand J Obstet Gynaecol. 2006;46(2):119–23. https://doi.org/10.1111/j.1479-828X.2006.00539.x.

    Article  Google Scholar 

  14. Soares RR, Maesta I, Colon J. Complete molar pregnancy in adolescents from North and South America: clinical presentation and risk of gestational trophoblastic neoplasia. Gynecol Oncol. 2016;142:496–500.

    Article  Google Scholar 

  15. Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013;33(4):406–11. https://doi.org/10.3109/01443615.2013.771159.

    Article  CAS  PubMed  Google Scholar 

  16. Rice LW, Berkowitz RS, Lage J, et al. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol. 1990;36(3):358–62. https://doi.org/10.1016/0090-8258(90)90142-8.

    Article  CAS  PubMed  Google Scholar 

  17. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO oncology committee. Int J Gynaecol Obstet. 2002;77(3):285–7.

    Article  Google Scholar 

  18. Ghaemmaghami F, Zarchi MK. Early onset of metastatic gestational trophoblastic disease after full-term pregnancy. Int J Biomed Sci. 2008;4(1):74–7.

    PubMed  PubMed Central  Google Scholar 

  19. Darby S, Jolley I, Pennington S, Hancock BW. Does chest CT matter in the staging of GTN? Gynecol Oncol. 2009;112:155–60.

    Article  Google Scholar 

  20. Ngan HYS, Benedet JL, Bender HG, et al. FIGO staging for gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2002;77:285–7.

    Article  Google Scholar 

  21. Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer. 2003;89(12):2197–201. https://doi.org/10.1038/sj.bjc.6601422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;1 https://doi.org/10.1002/14651858.CD008891.pub3.

  23. Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, Savage PM. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer. 2012;107:1810–4.

    Article  CAS  Google Scholar 

  24. Braga A, Torres B, Burlá M, Maestá I, Sun S, et al. Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6 months after uterine evacuation? Gynecol Oncol. 2016;143(3):558–64. https://doi.org/10.1016/j.ygyno.2016.09.012.

    Article  CAS  PubMed  Google Scholar 

  25. Taylor F, Short D, Winter MC, TIDY J, Savage PM, Sarwar N, et al. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. Gynecol Oncol. 2015;136(2):258–63.

    Article  CAS  Google Scholar 

  26. Lybol C, Sweep FCGJ, Harvey R, Mitchell H, Short D, Thomas CMG, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125(3):576–9.

    Article  CAS  Google Scholar 

  27. Prouvot C, Golfier F, Massadier J, You B, Lotz JP, Patrier S, et al. Efficacy and safety of second-line 5-day dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2018;28(5):1038–44. https://doi.org/10.1097/IGC.0000000000001248.

    Article  PubMed  Google Scholar 

  28. McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M, Seckl MJ, Newlands ES. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 2002;20(7):1838–44. https://doi.org/10.1200/JCO.2002.07.166.

    Article  CAS  PubMed  Google Scholar 

  29. Golfier F, Goffin F, Massardier J, Bolze P. Treatment of gestational throphoblastic neoplasia. ESGO gynaecological oncology textbook, 3rd ed.; 2016. https:www.esgo.org/media/2016/12/ESGO-3rd-edition-list-of-authors.

  30. Eoh KJ, Chung YS, Yim GW, Nam EJ, Kim S, Kim SW, Kim YT. Role of surgical therapy in the management of gestational trophoblastic neoplasia. Obstetr Gynecol Sci. 2015;58(4):277. https://doi.org/10.5468/ogs.2015.58.4.277.

    Article  Google Scholar 

  31. Elias KM, Shoni M, Bernstein M, Golstein DP, Berkowitz RS. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med. 2012;57(5–6):254–8.

    PubMed  Google Scholar 

  32. Osborne RJ, Filiac VL, Schink JC, Mannel RS, Behbakhi K, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016;128(3):535–42. 2

    Article  Google Scholar 

  33. Reda H, Elvira LV, Basem EL-D, Mahammad A, Eman T, et al. Second uterine curettage and number of chemotherapy courses in post molar gestational trophoblastic neoplasia. Obstet Gynecol. 2019;133(5):1024–31.

    Article  Google Scholar 

  34. New zealand Gynecologic Cancer group guidelines. 15/01/2014 Gestational throphoblastic Disease. https://nationalwomenshealth.adhb.govt.nz/assets/uploads/Gestational-Throphoblastic-Disease-Guidelines.pdf.

  35. Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003;110(1):22–6. PMID: 12504931.

    Google Scholar 

  36. Lorigan PC, Sharma S, Bright N, Coleman RE, Hancock BW. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol. 2000;78(3):288–92.

    Article  CAS  Google Scholar 

  37. Garrett LA, Garner E, Feltmate CM, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. Obstet Gynecol Surv. 2008;11:704–5. https://doi.org/10.1097/01.ogx.0000335639.50781.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

    Nomonde Mbatani

Authors
  1. Nomonde Mbatani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nomonde Mbatani .

Editor information

Editors and Affiliations

  1. Associate Professor, Department of Gynaecologic Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, India

    Bhagyalaxmi Nayak

  2. Professor & Head, Department of Obstetrics and Gynecology, King George’s Medical University, Lucknow, India

    Uma Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mbatani, N. (2021). Management of Low-Risk Gestational Trophoblastic Neoplasia. In: Nayak, B., Singh, U. (eds) Gestational Trophoblastic Disease. Springer, Singapore. https://doi.org/10.1007/978-981-33-4878-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-33-4878-3_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-33-4877-6

  • Online ISBN: 978-981-33-4878-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation